FCF Life Sciences Venture Capital Monitor – Europe 01/2021 published

FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Life Sciences Venture Capital Monitor – Europe 01/2021”.

The Monitor is a monthly published overview of venture capital trends in the European Life Sciences sector.

As of the end of January 2021 we identify the following current VC trends in Europe:

  • In 2021, overall Life Sciences funding has reached EUR 896m so far
  • Top 5 Deals exceed EUR 50m each, largest transaction amounted to EUR 160m in NewAmsterdam Pharma B.V.
  • BlackRock (USA) dominates the Top 5 Investors (by deal volume), followed by Bpifrance (France) and Life Sciences Partners (The Netherlands)
  • The Biotechnology sector received 70% of the total investment volume
  • Oncology dominates as the top indication

To access the full report, please click here.

By Dr. Mathias Schott, Sebastian Sommer and Alexander Kuhn